3.285

0.92% 0.025

Fulcrum Therapeutics Inc (FULC)

Overview News Price History Option Chain Financials Discussions Forecast

Fulcrum Therapeutics Inc stock is traded at $3.285, with a volume of 397.64K. It is up +0.92% in the last 24 hours and down -13.87% over the past month. Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Previous Close:

$3.26

Open:

$3.28

24h Volume:

397.64K

Relative Volume:

0.25

Market Cap:

$203.43M

Revenue:

$2.81M

Net Income/Loss:

$-97.34M

P/E Ratio:

-1.825

EPS:

-1.8

Net Cash Flow:

$-91.47M

1W Performance:

+1.54%

1M Performance:

-13.87%

6M Performance:

-57.55%

1Y Performance:

-15.42%

1-Day Range:

$3.21

$3.33

1-Week Range:

$3.13

$3.38

52-Week Range:

$2.865

$13.70

Fulcrum Therapeutics Inc Stock (FULC) Company Profile

Name

Fulcrum Therapeutics Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

617-651-8851

Address

26 LANDSDOWNE STREET, CAMBRIDGE, MA

Employee

Twitter

@fulcrumtx

Next Earnings Date

2024-11-05

Latest SEC Filings

FULC's Discussions on Twitter

Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-04-23	Downgrade	Goldman	Buy → Neutral
Mar-10-23	Downgrade	Credit Suisse	Outperform → Neutral
Mar-10-23	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-09-23	Downgrade	Stifel	Buy → Hold
Feb-28-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-24-23	Downgrade	BofA Securities	Neutral → Underperform
Nov-15-22	Initiated	Goldman	Buy
Mar-08-22	Initiated	Oppenheimer	Outperform
Mar-03-22	Upgrade	BofA Securities	Underperform → Neutral
Aug-11-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Apr-26-21	Resumed	Credit Suisse	Outperform
Mar-22-21	Initiated	Credit Suisse	Outperform
Mar-02-21	Initiated	Stifel	Buy
Oct-16-20	Initiated	Piper Sandler	Overweight
Aug-12-20	Downgrade	BofA Securities	Neutral → Underperform
Aug-12-20	Reiterated	H.C. Wainwright	Buy
Aug-12-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-19-20	Downgrade	BofA/Merrill	Buy → Neutral
Jun-17-20	Initiated	BTIG Research	Buy
Oct-03-19	Initiated	H.C. Wainwright	Buy
Aug-12-19	Initiated	BofA/Merrill	Buy

View All

Fulcrum Therapeutics Inc Stock (FULC) Latest News

02:29 AM

Vanguard Group Inc's Strategic Acquisition in Fulcrum Therapeuti - GuruFocus.com

02:29 AM

Nov 02, 2024

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Assenagon Asset Management S.A. - MarketBeat

Nov 02, 2024

Oct 31, 2024

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest Update - MarketBeat

Oct 31, 2024

Oct 26, 2024

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Rating of "Hold" from Brokerages - MarketBeat

Oct 26, 2024

Oct 21, 2024

We're Interested To See How Fulcrum Therapeutics (NASDAQ:FULC) Uses Its Cash Hoard To Grow - Yahoo Finance

Oct 21, 2024

Oct 14, 2024

Ratios in Focus: Analyzing Fulcrum Therapeutics Inc (FULC)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 14, 2024

Oct 11, 2024

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Oct 11, 2024

Zevra Stock Surges Close to 70% in 3 Months: Here's Why - MSN

Oct 11, 2024

Oct 10, 2024

The FULC Stock Puzzle: Unraveling Fulcrum Therapeutics Inc’s Fluctuating Performance - The InvestChronicle

Oct 10, 2024

Are Smart Investors Making the Right Decision? Fulcrum Therapeutics Inc (FULC) - SETE News

Oct 10, 2024

Further weakness as Fulcrum Therapeutics (NASDAQ:FULC) drops 12% this week, taking three-year losses to 88% - Simply Wall St

Oct 10, 2024

Oct 09, 2024